Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification SystemRAMIREZ, Elena; LAOSA, Olga; GUERRA, Pedro et al.British journal of clinical pharmacology. 2010, Vol 70, Num 5, pp 694-702, issn 0306-5251, 9 p.Article

GMP issues for recombinant plant-derived pharmaceutical proteinsFISCHER, Rainer; SCHILLBERG, Stefan; HELLWIG, Stephan et al.Biotechnology advances. 2012, Vol 30, Num 2, pp 434-439, issn 0734-9750, 6 p.Article

Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource Drug Products: Workshop summary reportCHEN, Mei-Ling; SHAH, Vinod P; HYSLOP, Terry et al.European journal of pharmaceutical sciences. 2011, Vol 44, Num 4, pp 506-513, issn 0928-0987, 8 p.Article

Prediction of the permeability of drugs through study on quantitative structure- : permeability relationshipSEO JEONG JUNG; SUN OK CHOI; SO YOUNG UM et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 41, Num 2, pp 469-475, issn 0731-7085, 7 p.Article

An overview about biopharmaceutics in EuropeAIACHE, Jean-Marc.European journal of drug metabolism and pharmacokinetics. 2005, Vol 30, Num 1-2, pp 19-27, issn 0378-7966, 9 p.Article

Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain -Biopharmaceutic and pharmacokinetic challengesSRINIVAS, Nuggehally R.European journal of drug metabolism and pharmacokinetics. 2009, Vol 34, Num 1, pp 7-10, issn 0378-7966, 4 p.Article

The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challengesSRINIVAS, Nuggehally R.European journal of drug metabolism and pharmacokinetics. 2011, Vol 36, Num 2, pp 49-59, issn 0378-7966, 11 p.Article

Oral drug absorption and the biopharmaceutics classification systemLENNERNÄS, H; ABRAHAMSSON, B; PERSSON, E. M et al.Journal of drug delivery science and technology. 2007, Vol 17, Num 4, pp 234-244, 11 p.Article

Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugsYU, Lawrence X; CARLIN, Alan S; AMIDON, Gordon L et al.International journal of pharmaceutics. 2004, Vol 270, Num 1-2, pp 221-227, issn 0378-5173, 7 p.Article

Production of biologically active recombinant human factor H in PhyscomitrellaBÜTTNER-MAINIK, Annette; PARSONS, Juliana; JEROME, Hanna et al.Plant biotechnology journal (Print). 2011, Vol 9, Num 3, pp 373-383, issn 1467-7644, 11 p.Article

Biopharmaceutics of β-cyclodextrin derivative-based formulations of acitretin in Sprague-Dawley ratsXIN LIU; LIN, Hai-Shu; SUI YUNG CHAN et al.Journal of pharmaceutical sciences. 2004, Vol 93, Num 4, pp 805-815, issn 0022-3549, 11 p.Article

Estimating production technical efficiency for the US biopharmaceutical industryLIN, Yi-Hsing; HONG, Chun-Fu.International journal of biotechnology. 2012, Vol 12, Num 3, pp 184-197, issn 0963-6048, 14 p.Article

Animal pharming, two decades onKIND, Alexander; SCHNIEKE, Angelika.Transgenic research. 2008, Vol 17, Num 6, pp 1025-1033, issn 0962-8819, 9 p.Article

Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changesSHARMA, Basant.Biotechnology advances. 2007, Vol 25, Num 3, pp 325-331, issn 0734-9750, 7 p.Article

Predicting Drug Disposition via Application of a Biopharmaceutics Drug Disposition Classification SystemBENET, Leslie Z.Basic & clinical pharmacology & toxicology (Print). 2010, Vol 106, Num 3, pp 162-167, issn 1742-7835, 6 p.Conference Paper

Dutch Society of Clinical Pharmacology and BiopharmacyBritish journal of clinical pharmacology. 2010, Vol 70, Num 6, pp 918-931, issn 0306-5251, 14 p.Conference Paper

Commercialization of biopharmaceutical and bioindustrial proteins from plants : Genetic and metabolic engineering for value-added traitsHOWARD, John A.Crop science. 2005, Vol 45, Num 2, pp 468-472, issn 0011-183X, 5 p.Article

Polymeric delivery systems for biopharmaceuticalsDINARVAND, Rassoul; DORKOOSH, Farid; HAMIDI, Mehrdad et al.Biotechnology & genetic engineering reviews. 2004, Vol 21, pp 147-181, issn 0264-8725, 35 p.Article

Strategic Biopharmaceutical Portfolio Development : An Analysis of Constraint-Induced ImplicationsGEORGE, Edmund D; FARID, Suzanne S.Biotechnology progress. 2008, Vol 24, Num 3, pp 698-713, issn 8756-7938, 16 p.Conference Paper

A special report on India's biotech scenario: Advancement in biopharmaceutical and health care sectorsCHAKRABORTY, Chiranjib; AGORAMOORTHY, Govindasamy.Biotechnology advances. 2010, Vol 28, Num 1, pp 1-6, issn 0734-9750, 6 p.Article

The production of biopharmaceuticals in plant systemsKARG, Saskia R; KALLIO, Pauli T.Biotechnology advances. 2009, Vol 27, Num 6, pp 879-894, issn 0734-9750, 16 p.Article

Immunogenicity of therapeutic proteins. Part 1: Impact of product handlingSHARMA, Basant.Biotechnology advances. 2007, Vol 25, Num 3, pp 310-317, issn 0734-9750, 8 p.Article

Biopharmaceutics classification by high throughput solubility assay and PAMPAOBATA, Kouki; SUGANO, Kiyohiko; MACHIDA, Minoru et al.Drug development and industrial pharmacy. 2004, Vol 30, Num 2, pp 181-185, issn 0363-9045, 5 p.Article

Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin AmericaIBARRA-CABRERA, Ricardo; MENA-PEREZ, Sandra Carolina; BONDANI-GUASTI, Augusto et al.Biotechnology advances. 2013, Vol 31, Num 8, pp 1333-1343, issn 0734-9750, 11 p.Article

Mammalian cell protein expression for biopharmaceutical production : Production of Recombinant ProteinsJIANWEI ZHU.Biotechnology advances. 2012, Vol 30, Num 5, pp 1158-1170, issn 0734-9750, 13 p.Article